Repository logo
 
Publication

Tumour infiltrating lymphocytes characterization in advanced non-small cell lung cancer with first-line immune checkpoint inhibitors treatment

2024-09Conference poster Open access
Simple item page
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorRuivo, L.
dc.contributor.authorFialho, M. Pinto
dc.contributor.authorBaptista, D.
dc.contributor.authorFilipe, J.
dc.date.accessioned2025-03-13T15:33:10Z
dc.date.available2025-03-13T15:33:10Z
dc.date.issued2024-09
dc.description.abstractBackground & objectives: Tumour-infiltrating lymphocytes (TILs) may have an impact on prognosis in non-small cell lung cancer (NSCLC) and may affect the efficacy of treatment. We aim to characterize TILs in advanced NSCLC with PD-L1 score>50%, treated with first-line immune checkpoint inhibitors. Methods: We performed a single-centre retrospective study. Patients diagnosed with advanced NSCLC with PD-L1>50%, from 2017 to 2023, were selected. Medical records and histological slides from the primary tumor specimens before treatment were reviewed. Immunohistochemistry for CD20, CD3, CD8 and PD-1 was performed. Tumour and stromal TILs were scored using 0%, 25% and 50% cut-offs. Results: A total of 34 patients were included. The median age was 64 years and 74% were male. The most prevalent histological type observed was adenocarcinoma (70%). Partial response to therapy was observed in 53% of patients, disease progression was seen in 44% and only 3% had a complete response. All the samples analyzed had a lymphocytic inflammatory infiltrate, with CD3+ T lymphocytes being the most prevalent. The type of inflammatory infiltrate overlapped in all treatment response subgroups. None of the cases showed more than 50% of tumor or stromal PD-1+ inflammatory cells. Conclusion: Despite therapy with immune checkpoint inhibitors, the majority of patients showed a partial response. It seems that the type of inflammatory infiltrate did not influence therapeutic response. Tumour and stromal PD-1+ inflammatory cells were the least prevalent and PD-1 was not relevant in TILs evaluation. Multi-centre randomized studies would provide more accurate data and allow performing statistical analysis regarding the prognostic value of TILs. A second biopsy could show if there are differences in the type of inflammatory infiltrate during treatment.eng
dc.identifier.citationRuivo L, Fialho MP, Baptista D, Filipe J. Tumour infiltrating lymphocytes characterization in advanced non-small cell lung cancer with first-line immune checkpoint inhibitors treatment. In: 36th European Congress of Pathology, Convention Centre Dublin (Ireland), September 7-11, 2024. Virchows Arch. 2024;485(Suppl 1):S450.
dc.identifier.doi10.1007/s00428-024-03880-y
dc.identifier.urihttp://hdl.handle.net/10400.21/21679
dc.language.isoeng
dc.peerreviewedyes
dc.publisherSpringer
dc.relation.hasversionhttps://link.springer.com/journal/428/volumes-and-issues/485-1/supplement
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectLung cancer
dc.subjectTumor-infiltrating lymphocytes
dc.titleTumour infiltrating lymphocytes characterization in advanced non-small cell lung cancer with first-line immune checkpoint inhibitors treatmenteng
dc.typeconference poster
dspace.entity.typePublication
oaire.citation.conferenceDate2024-09
oaire.citation.conferencePlaceDublin, Irlanda
oaire.citation.endPageS450
oaire.citation.issueSuppl 1
oaire.citation.startPageS450
oaire.citation.titleVirchows Archiv
oaire.citation.volume485
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Tumour infiltrating lymphocytes characterization in advanced non-small cell lung cancer with first-line immune checkpoint inhibitors treatment.pdf
Size:
5.21 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.03 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Posters